4530 Hisamitsu Pharmaceutical
- 4225.0
- -52.0-1.22%
Hisamitsu Pharmaceutical News
Hisamitsu Pharmaceutical: Notice of adoption of an open call for the vaccine/novel modality research and development project (public call) by AMED
Hisamitsu Pharmaceutical: Fatuship Fatuship Warmth Faith Z Zixus F Renewal Release Notice
Hisamitsu Pharmaceutical: Confirmation letter
Hisamitsu Pharmaceutical: Semi-annual report - Period 123 (2024/03/01 - 2025/02/28)
Hisamitsu Pharmaceutical: Notice of commencement of clinical development of HP-3150 (transdermal nonsteroidal pain treatment) in the US
Hisamitsu Pharmaceutical: Introduction of the “Trust Type Employee Shareholding Incentive Plan (E-Ship)”
Hisamitsu Pharmaceutical: [Summary]Consolidated Financial Results for the Second Quarter(Interim Period)of the Fiscal Year Ending February 28, 2025 [Japanese GAAP]
Hisamitsu Pharmaceutical: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending February 2025 [Japanese GAAP] (consolidated)
Hisamitsu Pharmaceutical: SAGA Global Research Center Announces Recruiting Collaborative Partners for the Purpose of Open Innovation
Hisamitsu Pharmaceutical: Announcement of the new sale of “Salonpas” 160 sheets “Fatus 5.0” 120 sheets
Hisamitsu Pharmaceutical: Announcements of individual stock subscription rights issuance details have been confirmed for stock-based compensation stock options.
Change report (exemption share certificates, etc.)
Hisamitsu Pharmaceutical: Confirmatory letter.
Hisamitsu Pharmaceutical: Quarterly report - Q1 of the 123rd period (03/01/2024 to 05/31/2024)
Hisamitsu Pharmaceutical: [Overview] Consolidated financial statements for the first quarter of the fiscal year ending on February 28, 2025.
Hisamitsu Pharmaceutical: February 2025, First quarter financial statements by Japanese standard (consolidated).
Hisamitsu Pharmaceutical: Announcements of individual stocks for the issuance of stock compensation type stock options (subscription rights).
Hisamitsu Pharmaceutical: Announcements of individual stocks: Announcement of results for the domestic Phase 2 clinical trial of HP-6050 (transdermal sedative).
Hisamitsu Pharmaceutical: [Postponed] Corporate Governance Report
Hisamitsu Pharmaceutical: Kusuri Pharmaceutical has chosen Mr. Mukai to be the image character for their new TV commercial for Escap. It will start airing nationwide from Saturday, June 8th, 2024 with a focus on morning self-care in the cell.
Analysis
Price Target
No Data
No Data